Pasireotide and Hepatic impairment
Result of checking the interaction of drug Pasireotide and disease Hepatic impairment for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of pasireotide causes elevations in ALT or AST. No dose adjustment is required in patients with mild hepatic impairment, but is required for patients with moderate hepatic impairment. The use of pasireotide should be avoided in patients with severe hepatic impairment. Regular monitoring of liver function test is recommended and interruption of treatment should be considered if abnormal values exceeding 5 times ULN or rising values are obtained during the course of therapy.
Generic Name: pasireotide
Brand Name: Signifor, Signifor LAR
Synonyms: n.a.
Pasireotide - zaburzenia czynności wątroby 
Pasireotide - insuficiência hepática 
Pasireotide - gangguan hati 
Pasireotide - gangguan hati 
Pasireotide - insufficienza epatica 
Pasireotide - insuffisance hépatique 
Pasireotide - Leberfunktionsstörung 
Pasireotide - deterioro hepático 
Pasireotide - печеночная недостаточность 
Pasireotide - karaciğer yetmezliği 
Pasireotide - اختلال كبدي 
Pasireotide - 肝功能不全